Biden Administration and Danco Laboratories Urge Supreme Court to Preserve Access to Abortion Pill

The Supreme Court's decision, expected by the end of June, will have nationwide implications for women's access to medication abortions.

The Biden administration and Danco Laboratories, the maker of the drug mifepristone, have urged the Supreme Court to preserve broad access to the widely used abortion pill.
The Justice Department and Danco defended the FDA's actions from 2016 and into 2021 as lawful, which included extending how late into a pregnancy mifepristone can be taken from seven weeks to 10 weeks, reducing the number of in-person visits required from three to one, and expanding the health care providers who can prescribe and dispense the drug.
The Supreme Court has intervened in the case once before, leaving the availability of the medication unchanged until it issues a ruling, which is expected by the end of June.
The challenge to mifepristone approval was brought by a group of doctors and other medical professionals represented by the conservative Christian legal group Alliance Defending Freedom.
Medication abortions have become increasingly common and accounted for more than half of all abortions in the U.S. in 2020.